Sandoz Recalls Cefazolin Due to Mispackaging, Opens Biosimilar Facility in Slovenia

▤ Summary

Sandoz recalled one lot of cefazolin injection after cartons were found to contain mislabeled penicillin G potassium vials. The company asked customers to stop using the product immediately and return the affected lot. FDA warned that administering the wrong antibiotic could cause serious harm, including treatment failure, allergic reactions, and cardiac arrhythmias. In separate news, Sandoz broke ground on a new biosimilar manufacturing facility in Slovenia and said the project expands its European production capacity and global supply chain resilience.

▦ Linked Companies